Breast cancer surveillance in women with hereditary risk due to BRCA1 or BRCA2 mutations

Clinical Breast Cancer

Volumn 5, Issue 4, 2004, Pages 260-268

  Robson, Mark ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast magnetic resonance imaging; Mammography; Ultrasound imaging

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; BREAST CANCER; BREAST EXAMINATION; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CLINICAL EXAMINATION; ECHOGRAPHY; FEMALE; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SELF EXAMINATION; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE;

EID: 9444248225     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2004.n.029     Document Type: Review

References (66)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71.
2. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378:789-792.
3. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002; 20:1480-1490.
4. Bluman LG, Rimer BK, Berry DA, et al. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol 1999; 17:1040-1046.
5. Chen WY, Garber JE, Higham S, et al. BRCA1/2 genetic testing in the community setting. J Clin Oncol 2002; 20:4485-4492.
6. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997; 277:997-1003.
7. Eisinger F, Alby N, Bremond A, et al. Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee. Ann Oncol 1998; 9:939-950.
8. Pichert G, Bolliger B, Buser K, et al. Evidence-based management options for women at increased breast/ovarian cancer risk. Ann Oncol 2003; 14:9-19.
9. NCCN Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/physician_gls/default.asp. Accessed September 13, 2003.
10. Vasen HF, Haites NE, Evans DG, et al. Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. Eur J Cancer 1998; 34:1922-1926.
11. Newman B, Mu H, Butler LM, et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998; 279:915-921.
12. Anton-Culver H, Cohen PF, Gildea ME, et al. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer 2000; 36:1200-1208.
13. Malone KE, Daling JR, Neal C, et al. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 2000; 88:1393-1402.
14. Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999; 91:943-949.
15. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 2000; 83:1301-1308.
16. Loman N, Johannsson O, Kristoffersson U, et al. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 2001; 93:1215-1223.
17. Thorlacius S, Sigurdsson S, Bjarnadottir H, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 1997; 60:1079-1084.
18. Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998; 352:1337-1339.
19. Tonin P, Weber B, Offit K, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996; 2:1179-1183.
20. Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999; 91:1241-1247.
21. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343:692-695.
22. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62:676-689.
23. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72:1117-1130.
24. Surveillance, Epidemiology, and End Results (SEER) Program, April 2003. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Available at: www.seer.cancer.gov. Accessed September 13, 2003.
25. Brekelmans CT, Seynaeve C, Bartels CC, et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 2001; 19:924-930.
26. Scheuer L, Kauff ND, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002; 20:1260-1268.
27. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56:265-271.
28. Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999; 91:1310-1316.
29. Kosters JP, Gotzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst Rev 2003; CD003373.
30. Hackshaw AK, Paul EA. Breast self-examination and death from breast cancer: a meta-analysis. Br J Cancer 2003; 88:1047-1053.
31. Thomas DB, Gao DL, Ray RM, et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 2002; 94:1445-1457.
32. Jatoi I. Screening clinical breast examination. Surg Clin North Am 2003; 83:789-801.
33. Barton MB, Harris R, Fletcher SW. The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? JAMA 1999; 282:1270-1280.
34. Tilanus-Linthorst MM, Bartels CC, Obdeijn AI, et al. Earlier detection of breast cancer by surveillance of women at familial risk. Eur J Cancer 2000; 36:514-519.
35. Warner E, Plewes DB, Shumak RS, et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001; 19:3524-3531.
36. Gui GP Hogben RK, Walsh G, et al. The incidence of breast cancer from screening women according to predicted family history risk: Does annual clinical examination add to mammography? Eur J Cancer 2001; 37:1668-1673.
37. Kriege M, Brekelmans CTM, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351:427-437.
38. Kuhl CK, Schrading S, Leutner CC, et al. Surveillance of "high risk" women with proven or suspected familial (hereditary) breast cancer: First mid-term results of a multi-modality clinical screening trial. Proc Am Soc Clin Oncol 2003; 22:2 (Abstract #4).
39. Warner E, Plewes DB, Shumak RS, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. J Am Med Assoc 2004; 292:1317-1325.
40. Chart PL, Franssen E. Management of women at increased risk for breast cancer: preliminary results from a new program. CMAJ 1997; 157:1235-1242.
41. Lalloto F, Boggis CR, Evans DG, et al. Screening by mammography, women with a family history of breast cancer. Eur J Cancer 1998; 34:937-940.
42. Kollias J, Sibbering DM, Blamey RW, et al. Screening women aged less than 50 years with a family history of breast cancer. Eur J Cancer 1998; 34:878-883.
43. Kerlikowske K, Carney PA, Geller B, et al. Performance of screening mammography among women with and without a first-degree relative with breast cancer. Ann Intern Med 2000; 133:855-863.
44. Gilliland FD, Joste N, Stauber PM, et al. Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 2000; 92:743-749.
45. Goffin J, Chappuis PO, Wong N, et al. Re: Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001; 93:1754-1755.
46. Tilanus-Linthorst M, Verhoog L, Obdeijn IM, et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 2002; 102:91-95.
47. Crystal P, Strano SD, Shcharynski S, et al. Using sonography to screen women with mammographically dense breasts. AJR Am J Roentgenol 2003; 181:177-182.
48. Kolb TM, Lichy J, Newhouse JH. Occult cancer in women with dense breasts: detection with screening US - diagnostic yield and tumor characteristics. Radiology 1998; 207:191-199.
49. Buchberger W, DeKoekkoek-Doll P, Springer P, et al. Incidental findings; on sonography of the breast: clinical significance and diagnostic workup. AJR Am J Roentgenol 1999; 173:921-927.
50. Kaplan SS. Clinical utility of bilateral whole-breast US in the evaluation of women with dense breast tissue. Radiology 2001; 221:641-649.
51. O'Driscoll D, Warren R, Mackay J, et al. Screening with breast ultrasound in a population at moderate risk due to family history. J Med Screen 2001; 8:106-109.
52. Gordon PB, Goldenberg SL. Malignant breast masses detected only by ultrasound. A retrospective review. Cancer 1995; 76:626-630.
53. Buchberger W, Niehoff A, Obrist P, et al. Clinically and mammographically occult breast lesions: detection and classification with high-resolution sonography. Semin Ultrasound CT MR 2000; 21:325-336.
54. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology 2002; 225:165-175.
55. Berg WA. Rationale for a trial of screening breast ultrasound: American College of Radiology Imaging Network (ACRIN) 6666. Am J Roentgenol 2003; 180:1225-1228.
56. Orel SG, Schnall MD. MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology 2001; 220:13-30.
57. Kneeshaw PJ, Turnbull LW, Drew PJ. Current applications and future direction of MR mammography. Br J Cancer 2003; 88:4-10.
58. Kuhl CK, Schmutzler RK, Leutner CC, et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000; 215:267-279.
59. Lo L, Rosen M, Schnall M, et al. Pilot study of breast MR screening of a high-risk cohort. Radiology 2001; 221:432.
60. Robson M, Morris EA, Kauff N, et al. Breast cancer screening utilizing magnetic resonance imaging (MRI) in carriers of BRCA mutations. Proc Am Soc Clin Oncol 2003; 22:91 (Abstract #362).
61. Podo F, Sardanelli F, Canese R, et al. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res 2002; 21(3 Suppl):115-124.
62. Stoutjesdijk MJ, Boetes C, Jager GJ, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001; 93:1095-1102.
63. Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, et al. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 2000; 63:53-60.
64. Warren R, Hayes C, Pointon LJ, et al. Is the specificity of breast MRI suitable for screening asymptomatic women at high risk? Radiology 2001; 221(suppl):432.
65. Morris EA, Liberman L, Ballon DJ, et al. MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol 2003; 181:619-626.
66. Liberman L, Morris EA, Benton CL, et al. Probably benign lesions at breast magnetic resonance imaging: preliminary experience in high-risk women. Cancer 2003; 98:377-388.